sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed Form 8.3 regarding its position in Avadel Pharmaceuticals plc. As of December 11, 2025, Vanguard holds a 5.74% interest in Avadel's US$0.01 ordinary shares, totaling 5,595,511 securities. This disclosure is in accordance with Rule 8.3 of the Irish Takeover Panel Act, 1997.
Recent transactions include a purchase of 3,625 shares and a sale of 2,108 shares, both at a price of 21.39 USD per unit. No cash-settled or stock-settled derivative transactions were reported. Additionally, there are no indemnity or option arrangements or agreements relating to voting rights or future acquisitions.
The disclosure confirms that Vanguard is not acting in concert with any other parties concerning Avadel. No supplemental information was appended to this filing.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.